Search This Blog

Friday, September 18, 2015

FDA Grants Priority Review for Amgen's Supplemental New Drug Application for Expanded Labeling of Kyprolis® (Carfilzomib) in Relapsed Multiple Myeloma

Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.